The subject of the present invention is to provide a transdermal absorption formulation with sufficient skin adhesiveness, low skin irritation, and excellent skin penetration of rivastigmine for exhibiting sufficient transdermal absorption capability. To solve the problem, the present invention provides a transdermal absorption formulation, which includes a support body, and an adhesive layer formed on the support body. The adhesive layer contains rivastigmine or its pharmaceutically tolerable salt, a thermoplastic elastomer, and nonvolatile hydrocarbon oil in an amount exceeding 50 parts by weight and not more than 800 parts by weight per 100 parts by weight of the thermoplastic elastomer. The thermoplastic elastomer is a mixture of styrene-isoprene-styrene tri-block copolymer and styrene-isoprene di-block copolymer. In the mixture, the content of the styrene-isoprene di-block copolymer is 20 weight% or more, the solution viscosity in 25 weight% toluene solution of the thermoplastic elastomer at 25 DEG C is 0.9 Pa.s or more, and the kinematic viscosity of the nonvolatile hydrocarbon oil at 40 DEG C is 80mm 2/s or more.本發明之課題為提供一種具有充分的皮膚黏著性同時皮膚刺激性低,且利伐斯的明(Rivastigmine)之皮膚透過性良好,並展現充分的經皮吸收性之經皮吸收製劑。本發明之解決手段為一種經皮吸收製劑,其係具有支持體、於該支持體上形成之黏著劑層,該黏著劑層係含有利伐斯的明或其藥學上可容許的鹽、熱可塑性彈性體及相對該熱可塑性彈性體100重量份,超過50重量份且在800重量份以下之不揮發性烴油,該熱可塑性彈性體為苯乙烯-異戊二烯-苯乙烯嵌段共聚物與苯乙烯-異戊二烯嵌段共聚物之混合物,且該混合物中之苯乙烯-異戊二烯嵌段共聚物的含量為20重量%以上,該熱可塑性彈性體的25重量%甲苯溶液的25℃中之溶液黏度為0.9Pa‧s以上,該不揮發性烴油的40℃中之動黏度為80mm2/s以上。
